PALO ALTO, Calif.--Drug discovery company Roche Biosciences here announced it has formed an alliance with Axys Pharmaceuticals of South San Francisco, Calif., to utilize Axys's functional genomics capabilities. Axys will apply its technologies utilizing C. elegans to evaluate the function of genes provided by Roche that may serve as drug targets in the development of therapies for pain and other nervous system disorders.
Roche will pay Axys an upfront fee and provide funding for research support. Axys has granted Roche an option to license targets discovered during the collaboration for the development of small molecule, diagnostic, and antisense products, with license payments, milestones, and royalties payable to Axys. Axys may also retain rights to develop gene therapy and therapeutic protein products acting upon targets discovered during the collaboration.